| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Omega-3-acid ethyl esters |
| Brand | Omacor® |
| Indication | As an adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy. Omacor® is also indicated for the treatment of endogenous hypertriglyceridaemia as a supplement to diet, when dietary measures alone are insufficient to produce an adequate response. |
| Assessment Process | |
| Full pharmacoeconomic assessment commissioned by HSE | 11/02/2013 |
| NCPE assessment completed | 19/04/2013 |
| NCPE assessment outcome | Reimbursement not recommended. |
The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.
